Terms: = Ovarian cancer AND FANCA, MGC75158, 2175, ENSG00000187741, FA-H, FA, FAA, FANCH, FA1, FACA AND Prognosis
14 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. An Acid Response IR780-Based Targeted Nanoparticle for Intraoperative Near-Infrared Fluorescence Imaging of ovarian cancer.
Song J; Ye H; Jiang S; Yang Y; Li X
Int J Nanomedicine; 2022; 17():4961-4974. PubMed ID: 36275480
[TBL] [Abstract] [Full Text] [Related]
3. Folic Acid-Modified Fluorescent-Magnetic Nanoparticles for Efficient Isolation and Identification of Circulating Tumor Cells in ovarian cancer.
Pan Y; Wang Z; Ma J; Zhou T; Wu Z; Ding P; Sun N; Liu L; Pei R; Zhu W
Biosensors (Basel); 2022 Mar; 12(3):. PubMed ID: 35323454
[TBL] [Abstract] [Full Text] [Related]
4. Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics.
Wang Z; Zhao S; Shi J; Meng F; Yuan J; Zhong Z
Acta Biomater; 2022 Jan; 138():443-452. PubMed ID: 34757229
[TBL] [Abstract] [Full Text] [Related]
5. Targeting Glutathione and Cystathionine β-Synthase in ovarian cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.
Santos I; Ramos C; Mendes C; Sequeira CO; Tomé CS; Fernandes DGH; Mota P; Pires RF; Urso D; Hipólito A; Antunes AMM; Vicente JB; Pereira SA; Bonifácio VDB; Nunes SC; Serpa J
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31635026
[TBL] [Abstract] [Full Text] [Related]
6. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.
Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D
Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403
[TBL] [Abstract] [Full Text] [Related]
7. Folic Acid Targeting for Efficient Isolation and Detection of ovarian cancer CTCs from Human Whole Blood Based on Two-Step Binding Strategy.
Nie L; Li F; Huang X; Aguilar ZP; Wang YA; Xiong Y; Fu F; Xu H
ACS Appl Mater Interfaces; 2018 Apr; 10(16):14055-14062. PubMed ID: 29620849
[TBL] [Abstract] [Full Text] [Related]
8. Polyvalent Folate-Dendrimer-Coated Iron Oxide Theranostic Nanoparticles for Simultaneous Magnetic Resonance Imaging and Precise cancer Cell Targeting.
Luong D; Sau S; Kesharwani P; Iyer AK
Biomacromolecules; 2017 Apr; 18(4):1197-1209. PubMed ID: 28245646
[TBL] [Abstract] [Full Text] [Related]
9. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses ovarian Tumor Growth.
Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
[TBL] [Abstract] [Full Text] [Related]
10. An integrated in silico approach to analyze the involvement of single amino acid polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 complex.
Doss CG; Nagasundaram N
Cell Biochem Biophys; 2014 Nov; 70(2):939-56. PubMed ID: 24817641
[TBL] [Abstract] [Full Text] [Related]
11. Abdominopelvic tuberculosis mimicking advanced ovarian cancer and pelvic inflammatory disease: a series of 28 female cases.
Liu Q; Zhang Q; Guan Q; Xu JF; Shi QL
Arch Gynecol Obstet; 2014 Mar; 289(3):623-9. PubMed ID: 24100800
[TBL] [Abstract] [Full Text] [Related]
12. Developing retroperitoneal anaplastic carcinoma with choriocarcinoma focus after ovarian non-gestastional choriocarcinoma: a case report.
Nikolić B; Ljubić A; Terzić M; Arandjelović A; Babić S; Vucić M
Vojnosanit Pregl; 2012 Dec; 69(12):1097-100. PubMed ID: 23424965
[TBL] [Abstract] [Full Text] [Related]
13. Breast cancer prognosis in relation to family history of breast and ovarian cancer.
Thalib L; Wedrén S; Granath F; Adami HO; Rydh B; Magnusson C; Hall P
Br J Cancer; 2004 Apr; 90(7):1378-81. PubMed ID: 15054458
[TBL] [Abstract] [Full Text] [Related]
14. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract] [Full Text] [Related]
